Tabletop Fire Pit Lawsuit Individuals who suffered severe burns, or families who lost a loved one in a tabletop fire pit explosion, may be eligible for financial compensation through a fire pit injury lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Selection of Tepezza Bellwether Lawsuits in Federal MDL Pushed Back to May 30 Judge agreed to delay bellwether trial picks for 60 days, but ordered Horizon Therapeutics to turn over all raw clinical trial data to plaintiffs, who indicate the drug manufacturer’s science was flawed. April 5, 2024 Irvin Jackson Add Your Comments The U.S. District Judge presiding over all Tepezza hearing loss lawsuits is giving defendants until the end of next month to turn over their list of bellwether cases, delaying the original deadline for selecting potential trial claims by 60 days. Plaintiffs identified their four Tepezza bellwether lawsuit picks on March 1, and the drug manufacturer was expected to select another four cases by April 1, after which the court will randomly select the final four cases that will go through cases-specific discovery in preparation for early trial dates. However, Horizon Therapeutics requested an extension, so that it could review additional medical records before selecting what they believe are the most representative claims for trial. The selections will come from over 100 product liability lawsuits currently pending in the federal court system, each involving similar allegations that plaintiffs experienced various forms of hearing damage from Tepezza, including persistent ringing in the ears known as tinnitus, and complete hearing loss. In many cases, the hearing loss persists long after the thyroid eye disease treatments, leaving users with irreversible hearing damage. Tepezza Lawsuits Did You or a Loved One Receive a Tepezza Injection? Side effects of Tepezza may cause permanent hearing problems. Lawsuits are being pursued over the drug maker’s failure to warn about the risk. Find out if qualify for a settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Tepezza Lawsuits Did You or a Loved One Receive a Tepezza Injection? Side effects of Tepezza may cause permanent hearing problems. Lawsuits are being pursued over the drug maker’s failure to warn about the risk. Find out if qualify for a settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Tepezza (teprotumumab-trbw) is a new-generation biologic treatment introduced by Horizon Therapeutics in January 2020, as the first medication approved to treat thyroid eye disease or bulging eyes, which is caused by hyperthyroidism and linked to Graves’ disease, resulting in inflammation of eye muscles, eyelids, tear glands and fatty tissues behind the eye. Although Tepezza infusions were originally intended as a niche treatment, with only a limited market, during the second year the drug was available in the United States sales doubled to $1.66 billion, and critics have expressed concern that Tepezza was aggressively marketed without adequately disclosing all of the potential risks. Given common questions of fact and law raised in complaints filed in federal courts nationwide, a Tepezza MDL (multidistrict litigation) was established in July 2023, centralizing the lawsuits before U.S. District Judge Thomas Durkin in the Northern District of Illinois for coordinated discovery and pretrial proceedings. As part of the coordinated management of the litigation, Judge Durkin has established a “bellwether” program, where a group of 12 representative cases will be selected to go through case-specific discovery in preparation for early trial dates, which will help the parties gauge how juries are likely to respond to certain evidence and testimony that will be repeated throughout various cases in the litigation. Tepezza Bellwether Selection Deadline Extended Horizon Therapeutics indicated the extension for selecting Tepezza bellwether lawsuits was necessary due to the number of medical records involved, and an on-going effort to find the most representative claims to be included in the bellwether discovery process. However, plaintiffs opposed the extension (PDF) in a March 12 brief to the court. “Horizon lacks good cause for its request,” plaintiffs wrote. “Horizon has obtained more than enough information in the past 90+ days to meet the stipulated (and already extended) deadline to select cases for discovery.” After a hearing held on March 20, Judge Durkin agreed to extend the deadline until May 30. However, in a Docket Entry (PDF) the Court noted that no further extensions of the deadline will be allowed. Plaintiffs’ Request for Raw Clinical Data Approved On March 19, a day before the hearing, the Judge issued a separate order (PDF) granting a request by plaintiffs for the raw clinical data for Tepezza, as well as seeking all records of payments Horizon made to healthcare professionals to promote and market Tepezza. Judge Durkin approved plaintiffs’ request for the data, despite opposition from the defendants, who attempted to argue the request was too broad. “The Court is not persuaded by defendant’s objections,” he wrote. “Defendant concedes the relevance of the raw data, which plaintiffs need to test their belief that defendant’s analysis was flawed. Moreover, the cost of anonymization, though undoubtedly considerable, should not be unduly burdensome for a litigant of the defendant’s means. Accordingly, the Court orders defendant to produce the raw clinical trial data.” However, Judge Durkin rejected the plaintiffs’ request for payment records, saying such payments are only marginally relevant to the litigation, and thus is overly broad and unduly burdensome. April 2024 Tepezza Lawsuit Update The bellwether selections are intended to prepare a group of representative cases for early trials, which the parties can use to gauge how juries are likely to respond to certain evidence that will be presented throughout the litigation, including allegations that users may have avoided Tepezza hearing problems if the drug maker had disclosed information about the risk, and instructed doctors to obtain hearing tests before and during treatments. In July 2023, the U.S. Food and Drug Administration (FDA) released a new version of the Tepezza prescribing information guide, which now adds many of the same hearing loss warnings plaintiffs indicate should have been included when the drug was first introduced. The new Tepezza label update now discloses that users have been left with severe and permanent hearing loss. It also indicates doctors should assess patients’ hearing before, during, and after Tepezza infusions, to avoid users experiencing permanent ear damage. While the outcome of Tepezza bellwether early trials will not be binding on other claims in the litigation, the average lawsuit payouts may influence eventual Tepezza settlement negotiations, which will be necessary to avoid each individual case being set for trial in the coming years. Tags: Hearing Damage, Hearing Loss, Horizon Therapeutics, Tepezza, Thyroid Eye Disease, Tinnitus Image Credit: | Written by: Irvin Jackson Senior Legal Journalist & Contributing Editor Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends. More Tepezza Lawsuit Stories First Tepezza Hearing Loss Lawsuit Set To Go Before Jury in June 2026 July 21, 2025 Tepezza Tinnitus and Hearing Loss Lawsuits Move Into Expert Discovery Phase June 11, 2025 Tepezza Lawyers Meet With MDL Judge To Review Status of Hearing Loss Lawsuits Today March 31, 2025 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermEmailThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Lawsuit Claims Cartiva Implant Caused Bone Loss and Nerve Damage in Big Toe (Posted: today) A Cartiva implant lawsuit blames the manufacturer for failing to warn patients about high failure rates for years after it began receiving implant complication reports. MORE ABOUT: CARTIVA IMPLANT LAWSUITJudge Orders Cartiva Implant Settlement Talks Before Trial in Aug. 2026 (07/28/2025)Cartiva Settlement Rumors Mount Again, as More Toe Implant Lawsuits Withdrawn and Trials Approach (06/26/2025)Failed Cartiva Implant Resulted in Need for Removal, Big Toe Fusion Surgery: Lawsuit (04/10/2025) Nearly 200 Women Pursuing BioZorb Lawsuits Over Complications With Breast Tissue Marker (Posted: yesterday) Hologic faces at least 183 BioZorb lawsuits, a number which continues to grow as the first bellwether trial is pushed back to January 2026. MORE ABOUT: BIOZORB LAWSUITFailed BioZorb Tissue Marker to Require Surgical Removal, Lawsuit Claims (08/04/2025)Problems With BioZorb Tissue Markers Not Adequately Disclosed by Manufacturer: Lawsuit (07/28/2025)Lawyers Preparing BioZorb Lawsuit To Go Before Jury on Sept. 8, 2025 (07/23/2025) Chemo Port Infection Lawsuits Over Bard, AngioDynamics Catheters Allege Faulty Design Promotes Bacterial Growth (Posted: 4 days ago) Lawsuits against Bard and AngioDynamics have been consolidated in separate MDLs, alleging that design defects in their implantable port catheter systems caused severe infections that were not properly disclosed. MORE ABOUT: BARD POWERPORT LAWSUITBard PowerPort Infection Lawsuit Chosen for First Bellwether Trial in Feb. 2026 (07/18/2025)Cook Medical Angiographic Catheter Recall Issued Following Multiple Reports of Serious Injury: FDA (06/27/2025)More Than 1,700 Bard PowerPort Lawsuits Now Filed in State and Federal Courts (06/03/2025)
Lawsuit Claims Cartiva Implant Caused Bone Loss and Nerve Damage in Big Toe (Posted: today) A Cartiva implant lawsuit blames the manufacturer for failing to warn patients about high failure rates for years after it began receiving implant complication reports. MORE ABOUT: CARTIVA IMPLANT LAWSUITJudge Orders Cartiva Implant Settlement Talks Before Trial in Aug. 2026 (07/28/2025)Cartiva Settlement Rumors Mount Again, as More Toe Implant Lawsuits Withdrawn and Trials Approach (06/26/2025)Failed Cartiva Implant Resulted in Need for Removal, Big Toe Fusion Surgery: Lawsuit (04/10/2025)
Nearly 200 Women Pursuing BioZorb Lawsuits Over Complications With Breast Tissue Marker (Posted: yesterday) Hologic faces at least 183 BioZorb lawsuits, a number which continues to grow as the first bellwether trial is pushed back to January 2026. MORE ABOUT: BIOZORB LAWSUITFailed BioZorb Tissue Marker to Require Surgical Removal, Lawsuit Claims (08/04/2025)Problems With BioZorb Tissue Markers Not Adequately Disclosed by Manufacturer: Lawsuit (07/28/2025)Lawyers Preparing BioZorb Lawsuit To Go Before Jury on Sept. 8, 2025 (07/23/2025)
Chemo Port Infection Lawsuits Over Bard, AngioDynamics Catheters Allege Faulty Design Promotes Bacterial Growth (Posted: 4 days ago) Lawsuits against Bard and AngioDynamics have been consolidated in separate MDLs, alleging that design defects in their implantable port catheter systems caused severe infections that were not properly disclosed. MORE ABOUT: BARD POWERPORT LAWSUITBard PowerPort Infection Lawsuit Chosen for First Bellwether Trial in Feb. 2026 (07/18/2025)Cook Medical Angiographic Catheter Recall Issued Following Multiple Reports of Serious Injury: FDA (06/27/2025)More Than 1,700 Bard PowerPort Lawsuits Now Filed in State and Federal Courts (06/03/2025)